UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Metastatic Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Trastuzumab|PROCEDURE: Erythromycin Breath Test (ERMBT)
Sponsor: University of Michigan Rogel Cancer Center
Collaborators: Genentech, Inc.